BCMA-Targeted ADC MEDI2228 Induces Deep Responses in Heavily Pretreated Myeloma
December 9th 2020December 9, 2020 — The BCMA-targeted antibody-drug conjugate MEDI2228 showed promising clinical efficacy in patients with relapsed/refractory multiple myeloma, with triple-refractory disease experiencing maintained responses.
Pemigatinib Trial Seeks to Build on Targeted Advances in Cholangiocarcinoma
September 22nd 2020An explosion of research in the field led to the approval of pemigatinib in April 2020 for patients with unresectable, previously treated advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement.
Dr. Bryce on the FDA Approval of Rucaparib in BRCA-Mutant mCRPC
May 20th 2020Alan H. Bryce, MD, discusses the accelerated approval of rucaparib (Rubraca) for the treatment of adult patients with BRCA mutation (germline and/or somatic)–associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor–directed therapy and a taxane-based chemotherapy.